The aim of translational medicine is to transform the fundamental understanding of human biology into effective health measures by setting up collaborations between Amsterdam Neuroscience and external stakeholders with assets (i.e. drugs, ATMPs or neurotechnology) in the field Neurology and Psychiatry. Translational medicine facilitates the characterization of disease processes, generates and validates novel hypotheses based on direct human observation and seeks collaboration the Principal Investigators of Amsterdam Neuroscience and medical chemistry experts in companies outside the campus to cross the gap between industrial R&D and the clinic development. The Industry Alliance Office facilitates this by initiating, facilitating and structuring the scientific discussions leading to project definition and contract execution of clinically oriented contracts sponsored by external stakeholder from biotech and pharma industry in the field of Translational Neuroscience, Neurology and Psychiatry.
As illustrated here Amsterdam Neuroscience has integrated its work with industry through working with so-called Translational Neuroscience Teams of principal investigators coming from various disciplines to perform a meaningful ‘carry-over’ of the latest insights from the bench, where curiosity driven research is performed, to the bedside, where purpose driven or clinical research is performed.
Vice versa, unresolved issues in the field of (companion) diagnostics, target engagement of (immuno-) therapies, imaging of the brain and/or the efficacy and/or side effects of novel therapies should be communicated back to the innovation teams,
to basic research experts but also to (graduate) students, residents, technicians and business developers.